Long Acting Injectable Cabotegravir for HIV Prevention | National AETC Support Center (NASC)

We'd like your feedback

Was this page helpful?

Yes

No

I found this page helpful because the content on the page:

Check all that apply

Had the information I needed

Was trustworthy

Was up-to-date

Was written clearly

I did not find this page helpful because the content on the page:

Check all that apply

Had too little information

Had too much information

Was confusing

Was out-of-date

Something was broken

Professional discipline

Primary professional discipline

Other reason or comment

Include your email address if you would like a response

Other reason or comment

Include your email address if you would like a response

Description:

This presentation provides information on the current evidence supporting the use of long acting injectable cabotegravir (CAB-LA) for HIV prevention, indication, safety, efficacy, as well as advantages and disadvantages of long acting injectable cabotegravir (CAB-LA).

Preview and Download

pptx

Preview

Download

Long Acting Injectable Cabotegravir for HIV Prevention